Merck asks SCOTUS for its $200M in Gilead patent dues, never mind the misconduct

Merck & Co. nabbed $200 million in damages after a hepatitis C patent fight with Gilead Sciences but quickly lost the whole shebang thanks to accusations of misconduct and fabricated testimony. And turns out, Merck doesn't want to let that cash go easily.